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Several amino acid changes have been previously implicated in adaptation of avian
influenza viruses to human hosts, among them the D701N change in the PB2
polymerase subunit that also is the main determinant of avian virus pathogenesis in
animal models. However, previous studies using recombinant viruses did not provide
conclusive information of the contribution of this PB2 residue to pathogenicity in human
influenza virus strains. We identified this mutation in an A(H1N1)pdm09-like human
influenza virus isolated from an infected patient with pneumonia and acute respiratory
failure, admitted to the intensive care unit. An exhaustive search has revealed PB2-
D701 as a highly conserved position in all available H1N1 human virus sequences in
NCBI database, showing a very low prevalence of PB2-D701N change. Presence of
PB2-701N amino acid correlates with severe or fatal outcome in those scarce cases
with known disease outcome of the infection. In these patients, the residue PB2-701N
may contribute to pathogenicity as it was previously reported in humans infected with
avian viruses. This study helps to clarify a debate that has arisen regarding the role of
PB2-D701N in human influenza virus pathogenicity.
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INFLUENZA VIRUS
Acute respiratory infections continue to be the main cause of acute illnesses worldwide and
influenza virus is one of the major contributors. The average global burden seasonal influenza
comes to be more than 600 million cases, 3 million cases of severe illness and 300,000–500,000
deaths per year worldwide1. Influenza A belongs to the family of negative stranded, segmented
RNA viruses known as Orthomyxoviridae, being the pathogens of major concern in veterinary
and public health. In their natural zoonotic reservoirs, the viruses are largely benign, causing
asymptomatic enteric infection in the wild aquatic birds (Webster et al., 1992), from here influenza
A viruses spread to domestic poultry, pigs, or people and they can evolve into strains that cause
mild to catastrophic disease.
1http://www.who.int
Frontiers in Microbiology | www.frontiersin.org 1 April 2017 | Volume 8 | Article 575
fmicb-08-00575 March 30, 2017 Time: 18:18 # 2
Nieto et al. Pathogenic Influenza A PB2-701N in Patients
Influenza virus possesses a negative-sense single-stranded
RNA genome divided into eight segments. The polymerase
subunits (PA, PB1 and PB2) and the nucleoprotein (NP) are
responsible for genome expression. These proteins associate to
each viral RNA segment to constitute the viral ribonucleoproteins
(Elton et al., 2005; Resa-Infante et al., 2010) that form
the minimum set of viral proteins required for viral RNA
transcription and replication (reviewed in Resa-Infante et al.,
2011; Fodor, 2013). The genome of influenza virus encodes for
10 major proteins, although the virus uses different mechanisms
to express alternative protein products from several genome
segments. These include alternative splicing of viral mRNAs or
non-canonical translation strategies. Ten viral proteins have been
studied extensively but five more proteins have recently been
identified, which would increase the degree of viral replication
control (Vasin et al., 2014).
Influenza A virus pathogenesis is a complex multigenic
mechanism, and pathogenic determinants are distributed
throughout the genome but, these determinants map mainly to
the polymerase genes, the surface glycoproteins hemagglutinin
(HA) and neuraminidase (NA) that are the targets of antibodies
that block the infection, and non-structural protein 1 (NS1), a
multifunctional protein that has a major role counteracting the
antiviral response (reviewed in Medina and Garcia-Sastre, 2011;
Rodriguez-Frandsen et al., 2015).
TRANSMISSION OF AVIAN INFLUENZA
VIRUSES TO MAMMALS: IMPLICATIONS
IN PATHOGENICITY
Most influenza A viruses infecting avian species in nature are
non-pathogenic but a few caused by strains of subtypes H5
and H7 are highly pathogenic to poultry and cause fulminating
disease with mortality close to 100% (Swayne and Pantin-
Jackwood, 2006; Capua and Alexander, 2007; Franca and Brown,
2014). Transmission of these highly pathogenic H5 and H7
avian influenza viruses to humans is not very frequent, although
the resulting disease is often severe or fatal (Claas et al., 1998;
Subbarao et al., 1998; Li et al., 2004; Horimoto and Kawaoka,
2005; Yen and Webster, 2009).
When infecting a new host influenza virus needs to
accomplish three crucial steps for successful infection and
propagation: (i) entry into the host cell, (ii) efficient replication
of the viral genome, and (iii) dissemination of progeny virions
into a new host (Sorrell et al., 2011). Preferential interaction of
the HA with different sialic acid cell receptors constitutes an
important host range determinant for influenza viruses (reviewed
in de Graaf and Fouchier, 2014). In addition, several described
mutations in the viral polymerase subunits are known to enhance
virus replication in mammalian cells and play an essential role
in virus adaptability to various hosts (Rodriguez-Frandsen et al.,
2015).
Analyzed H5 and H7 isolates from humans have mutations
involved in adaptation to the new host (Herfst et al., 2014;
Watanabe et al., 2014). Many of these are located in the
polymerase PB2 subunit, with E627K and D701N as the
most prevalent mutations (Subbarao et al., 1993; Hatta et al.,
2001; Steel et al., 2009; Chen et al., 2013; Gabriel et al.,
2013; Jonges et al., 2014), which are rarely present in human
circulating viruses. These changes in PB2 are also implicated
in pathogenesis in animal models. In H5N1 viruses isolated
from ducks in China, PB2-701N was the main pathogenicity
determinant in the mouse model (Shinya et al., 2004; Li et al.,
2005), and also partly determined the high pathogenicity of an
A/seal/Massachusetts/1/1980 (H7N7) virus (Gabriel et al., 2005).
In addition, experiments with recombinant viruses using the
A/Anhui/1/2013 avian H7N9 strain as a backbone and bearing
PB2-701N or PB2-701D showed higher viral titers for PB2-
701N than PB2-701D recombinant viruses in human A549-
infected cells and mouse lungs. Viral polymerase activity bearing
PB2-701N in avian viruses was also increased in reconstitution
experiments in human A549 cell line (Yamayoshi et al., 2015).
These data indicate that residue PB2-701N contributes to
augment pathogenesis in human cells and mice infected with
avian isolates.
Few protein residues from the PB1 polymerase protein have
been connected to host adaptation of influenza viruses. PB1
has a role in pathogenicity and polymerase activity and two
mutations in PB1, PB1-L473V and L598P, compensated for the
absence of PB2-627K within an attenuated reassortant virus
containing the H5N1 polymerase in a WSN background, both
in cell culture and in the mouse model (Xu et al., 2012). The
minimal set of mutations required for airborne transmission
of a H5N1 virus among ferrets included, in addition of the
PB2-E627K change, mutation PB1-H99Y (Linster et al., 2014),
both mutations together had a synergistic effect, increasing viral
polymerase activity and virus replication in mammalian cells.
PA subunit has been recognized as a key factor modulating
viral polymerase activity and pathogenicity in in vitro and in vivo
(reviewed in Rodriguez-Frandsen et al., 2015). Several mutations
in PA have been linked to enhanced virulence, including G631S
in an H5N1 avian virus (Hiromoto et al., 2000), or N409S in the
novel avian-origin H7N9 virus that may confer higher replication
in mammals (Yamayoshi et al., 2014). Mutations PA T97Y (Mehle
et al., 2012) and T552S (Song et al., 2009) are also involved in an
increased viral replication and pathogenicity of avian viruses in
mice.
PB2 SEGMENT OF INFLUENZA
A(H1N1)pdm09 VIRUS
The influenza A virus from the 2009 pandemic, A(H1N1)pdm09
virus, has segments of avian, human and porcine origin. This
virus showed high transmissibility, but relatively low virulence,
spread rapidly across the globe and caused the first pandemic
of the 21st century (Neumann et al., 2009). A(H1N1)pdm09
virus has an avian-lineage PB2 gene that lacks the E627K and
D701N substitutions that permit transmission and cooperate
in pathogenesis of avian-origin influenza viruses in humans or
other mammals. This virus nonetheless had a compensatory
PB2-Q591R substitution that rendered PB2-E627K unnecessary
for effective replication (Mehle and Doudna, 2009).
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Several reverse genetics studies have tested whether mutation
of the PB2 polymerase at residue 701 enhances virulence in
human A(H1N1)pdm09 viruses and obtained contradictory
results. Recombinant viruses were generated using the pandemic
A/Netherlands/602/2009 strain as a backbone. Enhanced
polymerase activity was found by mini-genome analysis using
a PB2 segment bearing PB2-701N compared with PB2-701D.
When mice and ferrets were infected with these two recombinant
viruses, PB2-701N-infected ferrets showed greater body weight
loss, although the virus with this mutation caused no other major
differences in global pathogenesis in mice and ferrets (Herfst
et al., 2010).
A different study used reassortant viruses containing the
four RNP genes (PB1, PB2, PA and NP genes) of the
representative A/California/04/2009 pandemic virus on the
background of the remaining four gene segments from the
A/New York/312/2001 (H1N1) seasonal human influenza virus.
In human cell cultures and in mice, the reassortant virus
containing PB2-701N substitution was attenuated (Jagger et al.,
2010). In contrast, in a more defined recombinant virus using
the pdm09-lineage A/New York/1682/2009 strain as backbone
and having PB2-701D or PB2-701N, higher replication rates
in human A549 cells and increased polymerase activity in a
mini-genome replication assay was found for the virus with
PB2-701N (Zhou et al., 2013). Moreover, the PB2-701N virus
was more pathogenic in the mouse model and showed more
efficient transmission in ferrets (Zhou et al., 2013). These
three reports do not provide conclusive results regarding the
contribution of PB2 residue 701 in human influenza virus
strains, and suggest distinct outcomes depending on genetic
background.
IDENTIFICATION OF 701N IN PB2
SUBUNIT OF AN INFLUENZA VIRUS
ISOLATED FROM AN INFECTED PATIENT
ADMITTED TO INTENSIVE CARE UNIT
In a search for specific changes in the polymerase of influenza
viruses that might contribute to viral pathogenicity in infected
patients, we evaluated the viruses present in the pharyngeal
exudate of patients diagnosed with influenza AH1N1pdm09-
linage infection, under 65 years of age admitted to the
intensive care unit (ICU) during the Spanish 2013–2014 epidemic
season. Respiratory samples were collected and delivered to the
Spanish National Influenza Center (CNM, ISCIII) for virological
characterization and virus isolation.
PB1, PB2 and PA segments sequences of all viruses
were obtained from Sanger sequencing of RT-PCR products
generated from the original clinical samples. We found a virus
bearing the PB2-D701N mutation (A/Aragon/270/2014) in the
clinical sample of one patient who met the above mentioned
requirements. The patient was a 60-year-old man admitted to
the hospital with onset of fever, asthenia, and cough persisted for
3 days. Past medical history included type 2 diabetes as comorbid
condition. The progressive deterioration of clinical conditions
with worsening wheezing, increased secretions and progressive
dyspnea at rest determined the admission to ICU for monitoring
and treatment. The patient was diagnosed with pneumonia
and acute respiratory failure after analytical test that displayed
a remarkable thrombocytopenia (71 × 103cells/µl) and chest
radiography showing increased density in lower left lung field.
After 3 days at the ICU with high flow nasal oxygenation (>21%),
with oseltamivir, ceftriaxone and azithromycin treatment the
patient showed good evolution and was discharged 8 days
later.
The analysis of the amino acid sequence of the polymerase
subunits showed that it had arginine (R) and glutamic acid (E)
at PB2 positions 591 and 627, respectively, which coincides with
the consensus sequence of the 2009 pandemic strains (Table 1,
upper).
ASSOCIATION OF PB2-701N WITH VIRAL
PATHOGENICITY IN THE INFECTED
PATIENT
Primary viral isolation was performed for further genome
analysis of this virus. Virus was amplified by one passage
in MDCK cells at low multiplicity of infection using the
titrated virus isolated from the original clinical sample. Total
viral RNA was isolated from purified virions as previously
described (Rodriguez et al., 2013), and full genome sequence
was determined by next-generation sequencing with TruSeq v3
chemistry and 50 bp single reads on an Illumina HiSeq 2000.
To determine the consensus sequence of the virus, coverage
and nucleotide composition of aligned reads were analyzed.
Nucleotide positions with an identity of ≥75% were considered.
Samtools mpileup (Li et al., 2009) and in-house php scripts were
used.
TABLE 1 | Characteristics of the Influenza A H1N1 viruses detected in
infected patients.
Human H1N1
Isolates
PB2 591 PB2 627 PB2 701 Clinical
manifestations
A/Aragon/270/2014 R E N Pneumonia and
acute respiratory
failure (ICU)#
A/Uganda/MUWRP-
111/2009
R E N Unknown
A/Wisconsin/51/2009 R E N Unknown
A/Singapore/GP3828/2010 R E N Unknown
Most A(H1N1)pdm09 R E D Mostly mild
Human H1N1
isolates from swine
origin
PB2 591 PB2 627 PB2 701 Clinical
manifestations
A/Jiangsu/ALS1/2011 Q E N Fatal
A/Jiangsu/1/2011 Q E N Unknown
A/Switzerland/9356/2009 Q T N Unknown
A/Switzerland/5165/2010 Q E N Unknown
#Requiring admission to Intensive care unit.
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The full viral genome sequencing allowed the comparison
of the complete amino acid sequence of this virus
A/Aragon/270/2014 with mild-case viruses from the same
influenza season isolated in the sentinel medical centers. The
comparison showed three amino acid changes; PB2-D701N,
HA-K403R and NA-L415M. A search in the NCBI Influenza
Virus Resource database2 indicated that NA-L415M change has a
prevalence >1% in human influenza A(H1N1)pdm09 virus NA
proteins, whereas PB2-D701N and HA-K403R had a prevalence
between 0.05 and 0.10%. The PB2-D701N change was present in
100% of the A/Aragon/270/2014 viral sequence reads, but change
HA-K403R was present in 85% of total reads. The remaining
15% of the total reads corresponded to the nucleotide present in
mild-case circulating viruses.
The K403R HA change is not described as a pathogenicity
determinant of those reported for A(H1N1)pdm09 (Safronetz
et al., 2011; Martinez-Romero et al., 2013) or H5N1 viruses
(Hulse et al., 2004; Heider et al., 2015). In addition, all the
described positions in the introduction section, which may
mutate to increase viral pathogenicity in mammals, are identical
to those of the mild-case human viruses. This data suggests that
the previously described PB2-D701N change might be in this
patient, the main viral contributor to severe outcome of the
infection.
LOW PREVALENCE OF INFLUENZA
PB2-701N VIRUS IN HUMANS
An exhaustive examination of NCBI database showed that only 8
out of 7562 (prevalence 0.105%) PB2 segment sequences detected
in H1N1 virus infected patients contained a different amino acid
than PB2-D701 from April 1950 until March 2016 (Tables 1, 2),
indicating a highly conservancy of this position in H1N1 virus
detected in humans. Seven of them bore PB2-D701N change
(eight, including the viral isolate here described, prevalence
0.105%), and corresponded to human A(H1N1)pdm09-linage
isolates obtained from the start of the 2009 pandemic until
March 2016. Comparison of the HA sequences of these isolates
indicated that four had a swine origin HA gene, and thus
corresponded to humans infected directly with porcine viruses
(0.052%) (Table 1 lower, Table 2). The death 40 days post-
infection of a 3-year-old child was the unique report among
these patients infected with porcine strains (Qi et al., 2013).
Sequence analysis of the other three human isolates containing
PB2-D701N mutation indicated that their HA protein was
the human protein present among circulating A(H1N1)pdm09-
linage viruses (Table 1, upper). Thus, the total prevalence of
H1N1 viruses of human origin containing PB2-701N from
April 1950 until March 2016, including A/Aragon/270/2014, is
four from a total of 7562 (0.052%) available sequences in the
NCBI database, and all of them are of A(H1N1)pdm09-linage
(Table 2). The genome of A/Aragon/270/2014 has been deposited
in the NCBI database under accession no. “Pending.” The NCBI
2http://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nph-select.cgi
database accession numbers of the viral isolates described in this
study are indicated in Supplementary Table 1.
To determine the spread in the community of A/Aragón/
270/2014 virus found in the infected patient admitted to ICU, we
further sequenced PB2 segments of 13 human A(H1N1)pdm09-
linage viruses detected from positive influenza cases studied
during the same influenza season (2013–2014) and the same
geographical region. All 13 influenza samples bore PB2-701D,
indicating that PB2-701N influenza viruses were not commonly
circulating in the area, and remarkably the only case here
described containing PB2 D701N mutation was associated with
admission to ICU.
DISCUSSION
Only four influenza A H1N1 human viruses containing
glutamine at position 701 of the PB2 polymerase subunit
are reported in the Influenza Virus Resource database,
which indicates that sporadic mutation at this position is
very infrequent (Table 2). Among them, the unique virus
characterized (A/Aragon/270/2013) was isolated from a patient
aged under 65 with pneumonia and acute respiratory failure,
admitted to ICU. Although the importance of the HA-K403R
change also present in this virus has not been previously
characterized for pathogenesis of human influenza strains
(Hulse et al., 2004; Safronetz et al., 2011), this mutation was
identified in a human influenza A H1N1 virus of swine origin
(A/Saskatchewan/5351/2009), which produced mild symptoms
in the infected patient (Bastien et al., 2010). These data suggest
that the previously described PB2-D701N change may be the
main virulence determinant of this viral isolate.
A secondary pneumococcal infection following influenza has
been detected in this patient. Influenza virus infection can induce
an immunosuppressed state, which is associated with increased
incidence of bacterial infections such as S. pneumoniae. It has
been described that resident macrophage population declines
as influenza progresses (reviewed in Smith and McCullers,
2014). Alveolar macrophages play a central role in bacterial
establishment, growth, and eradication as revealed in a model
analysis. The dose-dependent invasive ability of pneumococci
was solely dependent on the number and phagocytic ability of
resident macrophages initially present (Smith and McCullers,
2014). In addition, virus-mediated patches of desquamated
epithelium allow bacteria to adhere and invade with increase
vigor (reviewed in Mina and Klugman, 2014). Thereby, infection
with a particularly virulent influenza strain would exacerbate
these processes that together with the respiratory tract damage
may enhance the subsequent opportunistic bacterial infections.
Regarding the underlying medical conditions of the
A/Aragon/270/2013 infected patient, past medical history
included type 2 diabetes. It needs to be considered that diabetes,
is among the comorbidities involved in a severe outcome of
influenza virus infection and it triples the risk of hospitalization
after influenza A(H1N1)pdm09 infection (Jimenez-Garcia
et al., 2013). However, the results of multivariate analysis have
suggested that possibly concomitant conditions such as obesity,
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TABLE 2 | Prevalence, origin, and disease outcome data related to H1N1 viruses bearing changes at position 701 of influenza PB2 polymerase subunit.
PB2-D701 position Total H1N1 human
isolates (%)
Swine origin H1N1
human isolates (%)
A(H1N1)pdm09-linage
human isolates (%)
Cases with known
disease outcome (%)
Severe/fatal
outcome (%)
N amino acid change 8a/7562 (0.105) 4/7562 (0.052) 4/7562 (0.052) 2/8 (25) 2/2 (100)
Other amino acid change 1b/7562 (0.013) 0/7562 (0) 1/7562 (0.013) 0/1 (0) 0/1 (0)
a: Including viral isolate sequences available in Influenza Resource Database and viral isolate described in this study. b: Amino acid change PBZ-D701Y.
frequently found among diabetic persons, highly increases
the risk of very severe infection or even death, and not only
diabetes itself (Jimenez-Garcia et al., 2013). The patient from
whom A/Aragón/270/2014 virus was isolated did not have
obesity and his levels of glycated hemoglobin were within the
levels of the control population indicating a good control of
blood glucose levels upon infection. In addition, during the last
12 years previous to the influenza virus infection here described
it does not appear in the clinical history of the patient important
infections or reasons for medical consultation attributable to the
diabetes. Nevertheless, it cannot be excluded a contribution of
this factor to the infection outcome.
Human infections with swine influenza viruses appear
to occur infrequently (Schrauwen and Fouchier, 2014) and
scarce swine-origin influenza viruses have not been previously
associated with human severe/fatal outcome of infection (CDC,
2013). Only four patients have been described infected with swine
origin viruses bearing PB2-701N. The infection outcome was
reported in only one of them and it was a deceased patient
(Table 1, lower) (Qi et al., 2013). The analysis of the deceased-
case virus sequence showed that amino acids at positions above
described other than PB2 701N, whose mutations have been
related to increased pathogenicity in mammals, are similar to
those of mild-case human viruses and A/Aragon/270/2014 virus.
This data suggests that these positions are not contributing to
an increased pathogenicity of this virus. Thereby, although other
viral or host determinants may have cooperated to this outcome,
once again these data point out that PB2-701N amino acid may
contribute to a severe or fatal outcome of the infection in humans.
As indicated above the PB2-D701N change produces
increased polymerase activity in mini-replicon assays in the
context of A(H1N1)pdm09 polymerase. More active polymerase
would support a higher viral replication and consequently
potential increased pathogenicity. However, PB2-D701N
mutation is very scarcely found suggesting that it does not
circulate in humans, but that it may be generated in some
infected patients, probably as the result of particular virus–host
interactions that allow the growth and establishment of the virus
carrying this mutation.
An important question is why a virus with a potential
increased replication does not spread among human population.
One possibility is that viruses containing this mutation have
high replication rates but have poor transmission ability among
humans, in contrast to the high transmissibility rate that
this mutation confers to avian strains for human infections.
A different scenario for the barely dispersion of the PB2-N701
virus could be related with its increased virulence. It is possible
that patients infected with the virus, are most of the time admitted
to the ICU as a consequence of a severe infection outcome, which
results in the confinement of the virus reducing its dissemination.
In summary, the data indicate that an Asparagine at position
701 of influenza PB2 polymerase subunit could be contributing
to the viral pathogenicity in humans. Future screening of virus
containing this change could be crucial for final establishment of
this relation.
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